91Ï㽶ÊÓƵ Invests $200 Million to Expand Biologics Capacity and Capabilities
SOMERSET, N.J. – January 7, 2019— 91Ï㽶ÊÓƵ. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers. The investments, phased over a three-year program, will be undertaken at the company’s biologics manufacturing sites in Madison, Wisconsin and Bloomington, Indiana. This follows a recent to invest $14 million in packaging capabilities at the Bloomington site.
Mammalian cell culture capacity will be increased at Madison with the build out of two new suites, each with a 2 x 2,000 liter single-use bioreactor system, providing additional clinical and commercial production capacity at the 2,000 or 4,000-liter batch scale. Work is expected to be completed by mid-2021 and will more than double 91Ï㽶ÊÓƵ’s commercial biomanufacturing capacity.
Additionally, fill/finish capacity at the Bloomington site will be expanded by 79,000 sq. ft., with both GMP and non-GMP capabilities. A high-speed flexible vial line, utilizing both ready-to-use (RTU) components and bulk filling, at a filling speed of 300 units per minute, will be installed along with a high-speed flexible syringe/cartridge line with a filling speed of over 300 units per minute, and a fully automated vial inspection machine.
“The expansions at both sites will support our customers’ development programs and commercial launches,†commented Barry Littlejohns, President, 91Ï㽶ÊÓƵ Biologics and Specialty Drug Delivery. He added, “91Ï㽶ÊÓƵ’s continued investments in innovative technologies and flexible capacity allow us to offer the most comprehensive solutions to bring important and innovative treatments to market faster.â€
Opened in April 2013 and recently expanded with the addition of a 2 x 2,000-liter single-use bioreactor suite and new laboratories, 91Ï㽶ÊÓƵ Biologics’ Madison facility specializes in development, manufacturing and analytical services for new biological entities and biosimilars. It is the home of the company’s proprietary GPEx® cell line development technology, used to create high-yielding mammalian cell lines. This year, 91Ï㽶ÊÓƵ celebrated a significant milestone when the tenth biologic therapy utilizing GPEx technology was approved for commercial use. The Madison facility was designed for cGMP production from 10 to 4,000-liter scale, providing flexibility in batch size to meet client needs.
91Ï㽶ÊÓƵ’s 875,000-square-foot biologics development and manufacturing facility in Bloomington employs a growing staff of 900 employees, with deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges. The site also recently achieved regulatory approval for a twentieth commercial product.
Investor Contact:
Thomas Castellano
91Ï㽶ÊÓƵ.
(732) 537-6325
[email protected]
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0)161 728 5880
[email protected]
About 91Ï㽶ÊÓƵ Biologics
91Ï㽶ÊÓƵ Biologics provides advanced technologies and tailored solutions for biologic and biosimilar development, from DNA to commercial supply, through our extensive Biologics network including: Madison, Wisconsin; Emeryville, California; Kansas City, Missouri; Morrisville, North Carolina, Bloomington, Indiana; and Brussels, Belgium. For more information on 91Ï㽶ÊÓƵ Biologics, visit www.catalent.com/biologics.
About 91Ï㽶ÊÓƵ.
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.